THE ROLE OF MOLECULAR OR CYTOGENETIC RESPONSE AS A FAVORABLE PROGNOSTIC FACTOR BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

Tyrosine kinase inhibitors (TKIs) have revolutionized therapy for patients with chronic myeloid leukemia (CML) over the last two decades. However, some patients still do not achieve an adequate response to these drugs, and hematopoietic stem cell transplantation (HSCT) is indicated in this scenario. We present the results of a 20 -year follow-up study of 70 patients who underwent transplantation after TKI failure. The primary objective of this study was to evaluate overall survival (OS) and the secondary objective was to evaluate the outcomes of relapse -free survival (RFS), GVHD-free, relapse -free survival (GFRS) and the incidences of relapse (RI), non -relapse mortality (NRM), acute and chronic GVHD. Median survival was 11 years, with a 1 -year OS of 70% (57.8 to 79.3) and a 5 -year OS of 57.7% (45.1 to 68.5). The estimated 5 -year OS was not different for CP1 (60%) versus advanced stages (45%); P = .60. The degree of response immediately before transplantation was directly associated with worse outcomes [HR 5.89 (1.19-29.16); P = .03] for patients with only a hematological response compared with patients with a cytogenetic or molecular response. This study corroborates the potential of HSCT in the scenario of therapeutic failure and highlights the role of molecular or cytogenetic response as a potential target to be achieved before transplantation. (c) 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.